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Abstract
Evidence (‘data’) is at the heart of EFSA’s 2020 Strategy and is addressed in three of its operational
objectives: (1) adopt an open data approach, (2) improve data interoperability to facilitate data
exchange, and (3) migrate towards structured scientiﬁc data. As the generation and availability of data
have increased exponentially in the last decade, potentially providing a much larger evidence base for
risk assessments, it is envisaged that the acquisition and management of evidence to support future
food safety risk assessments will be a dominant feature of EFSA’s future strategy. During the breakout
session on ‘Managing evidence’ of EFSA’s third Scientiﬁc Conference ‘Science, Food, Society’, current
challenges and future developments were discussed in evidence management applied to food safety
risk assessment, accounting for the increased volume of evidence available as well as the increased IT
capabilities to access and analyse it. This paper reports on presentations given and discussions held
during the session, which were centred around the following three main topics: (1) (big) data
availability and (big) data connection, (2) problem formulation and (3) evidence integration.
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1. Introduction
Evidence (‘data’) is at the heart of EFSA’s 2020 Strategy (EFSA, 2015a). Within the framework of
strategic objective 2, ‘Widen EFSA’s evidence base and maximise access to its data’, EFSA is addressing
three underpinning operational objectives: (1) adopt an open data approach, (2) improve data
interoperability to facilitate data exchange and (3) migrate towards structured scientiﬁc data.
Much of the data and evidence considered by the European Food Safety Authority (EFSA) is being
made publicly accessible via its scientiﬁc data warehouse (EFSA, online), knowledge junction (Zenodo,
online), repositioned EFSA Journal1 on Wiley as well as European open data portals (European
Commission, online). EFSA’s published outputs are now available as JATS XML, the international
standard for journal articles. The Authority is also piloting migration from PDF dossier applications in
the regulated product area towards electronic dossier submission and automatic publication of non-
conﬁdential information using structured formats based, as far as possible, on existing international
standards to enable data access and reuse.
The Royal Society has recently recommended that ‘scientists should communicate the data they
collect and the models they create’ (The Royal Society, 2012), so that scientiﬁc conclusions are
intelligible and assessable, plus being reusable by other scientists: data used for scientiﬁc papers
should be accessible, intelligible, assessable and usable.
The generation and availability of data have increased in the last decade, as well as the IT capabilities
to access and analyse them, potentially providing a much large evidence base for future (food safety)
risk assessments. It is widely acknowledged that some 90% of the data in general in the world today
has been created in the last two years and about 75% of these data are unstructured (Marr, 2018).
To that end, a full-day session at EFSA’s third Scientiﬁc Conference on ‘Science, Food and Society’
(Parma, Italy, 18–21 September 2018)2 was dedicated to the topic of ‘evidence management’. The
session started from the increased availability of potential evidence, and then it progressed into
understanding how to frame and formulate problems so that only relevant evidence is taken into
consideration. The session closed with a discussion on how relevant complex evidence can be
integrated into a meaningful result. The session developed from earlier EFSA discussions on (big) data
and evidence (EFSA, 2019) and brought together multidisciplinary speakers from industry, academia,
the European Commission and food safety authorities to discuss developments, opportunities and
challenges relevant to the acquisition and management of evidence to support future food safety risk
assessments. It is anticipated that the outcome of this session will help to inform the next EFSA
Strategy 2021–2027 (on data and evidence management).
Here, we ﬁrst brieﬂy summarise the status of data management in EFSA (EFSA, 2019), and
subsequently summarise presentations made and discussions held during the breakout session
‘managing evidence’. These contributions were centred around the following three main topics: (1)
(big) data availability and (big) data connection, (2) problem formulation and (3) evidence integration.
The ﬁrst topic considered the current situation of the increasing availability of a wide range
evidence, from a myriad of different sources, at very different levels of relevance and reliability, with a
rapidly increasing level of automation in their generation. Key elements included having access to
relevant data and its extraction, and relevance of continually changing evidence. More relevant
technologies in area of scientiﬁc risk assessment were discussed: molecular biology, ‘omics, big data,
the internet of things. Blockchain technology was discussed as a promising technology for data
traceability and traceability in the whole food chain.
The second topic aimed to underline the increasing importance of problem formulation in a context
in which there are continually increasing amounts of data available, and a resulting need to focus on
questions that are relevant. Problem formulation has a human and societal dimension, and is
important to determine the acceptable residual level of uncertainty (e.g. Devos et al., 2019a,b).
The third topic dealt with the weight of evidence assessment including evidence integration and
uncertainty analysis and explored the applications of machine learning and artiﬁcial intelligence (AI) in
scientiﬁc risk assessments.
1 https://efsa.onlinelibrary.wiley.com/journal/18314732
2 All conference materials are available at https://www.efsa.europa.eu/en/events/event/180918
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2. Thematic areas
2.1. Scientiﬁc innovation and new data streams
It is widely acknowledged that the vast majority of world-wide data has been created in recent
years and is unstructured. With this trend increasing exponentially, the data available for analysis will
expand continuously in terms of all the ‘Vs’ of big data, including velocity, volume and variety (Gartner,
online), and veracity and value (see below). EFSA is actively engaged in working with the scientiﬁc
community to identify how data are created and captured in innovative research and what new and
currently unknown or unexplored data streams EFSA should be accessing to further expand its
evidence base (EFSA, 2019).
2.2. Distributed data: from ‘data collection’ to ‘data connection’
Increasingly, the nature of EFSA’s scientiﬁc work requires access to data not traditionally collected
by the agency and it is timely to consider a shift in focus from ‘data collection’ to ‘data connection’. An
Application Processing Interface (API) is the back-end technology to facilitate this transition –
effectively an electronic ‘shop front’ to EFSA’s data for machines. Exploration of mechanisms to
automatically connect to and retrieve data from outside the EFSA is a logical next step. Ultimately, an
ecosystem of APIs has the potential to provide EFSA with access to up-to-date, relevant data without
duplication and storage over-heads. Each data creator in the ecosystem could collect, validate, store,
maintain and operate appropriate access controls. In addition, the availability of cloud computing will
enable more effective processing of data (EFSA, 2019).
2.3. Quantitative and data driven methods: transforming (big) data into
scientiﬁc evidence
Having identiﬁed and accessed relevant new data sources, the next challenge will be to ensure that
the data quality (ﬁtness-for-purpose) is appropriate to meet EFSA’s standards of scientiﬁc rigour
(Devos et al., 2019a,b). Building on the conclusions of the EFSA Prometheus report (EFSA, 2015b),
quantitative methods for data appraisal and validation will need to continue to develop in parallel with
changing approaches to data identiﬁcation and retrieval to ensure its appropriate transformation into
sound scientiﬁc evidence. EFSA’s work in advancing its approach to automation, machine learning and
AI will build on ongoing work towards interoperability standards and domain ontologies. There are
considerable opportunities to work in collaboration with stakeholders to test complex predictive models
and machine learning in risk assessment, expert knowledge elicitation and the tracing of food
contamination events throughout the food chain (EFSA, 2019).
2.4. Exploring the living opinion: from static PDF documents to real-time
analysis and communication
A key feature of data use in risk assessment is timeliness and this will continue to increase in
importance in the future. Moving towards more real-time data analysis and risk communication is
expected to be increasingly important. Making that analysis readily accessible to practitioners,
scientists and consumers in a reproducible and transparent way will also be driven by modern data
visualisation and dissemination services (EFSA, 2019).
3. Summary of presentations
The breakout session was designed to provide information on current challenges and future
developments in evidence management within EFSA and food safety risk assessment, and to explore
the associated level of automation in the above-mentioned thematic areas. The session considered
three main aspects:
• (big) data availability and (big) data connection;
• problem formulation;
• evidence integration.
These aspects are currently handled by humans and/or by machines. Problem formulation is
expected to remain largely carried out by humans. Evidence integration is currently mostly based on
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human input, but it is expected to be increasingly addressed electronically. (Big) data availability and
(big) data connection are already mainly managed electronically.
The ﬁrst topic has been analysed in its different dimensions, from both theoretical and practical point
of views: the Fourth Revolution in mankind evolution that has taken us into the data age; a practical
example how big data can be used for evidence-based decisions by regulatory decision making; a
practical example on blockchain as a technology that leads us into improved trust in evidence
management; a practical example of successful application of software to reduce animal testing at
predicting toxicity of chemicals; the social and technical challenges in sharing and reusing big data.
The second topic has been analysed in both its human and societal dimensions: the importance of
crowdsourcing and communities of knowledge in contributing to societal problems; how machines can
augment human performance via sense-making models; how open source software can result as a
valid alternative in times of shrinking resources.
The third topic has been explored through analysis of ‘omics disciplines and technologies, and
through approaches as mode of action (MOA) and adverse outcome pathways (AOP), and
methodologies as weight of evidence (WoE) and multicriteria decision analysis (MCDA).
3.1. (Big) data availability and (big) data connection
3.1.1. The Fourth Revolution
The session opened with a presentation on ‘the Fourth Revolution’: after the ﬁrst three industrial
revolutions (steam engine, electricity and Internet), the Fourth Revolution is the explosion of data.
Science for risk assessment makes huge strides in the age of big data and high-performance
computing. Science can feed ever clearer and faster risk assessment, and real-world – and real-time –
evidence from dynamic data can both improve the iterative maintenance of risk knowledge and create
opportunities for more efﬁcient and effective management steps.
These revolutionary changes affect a world where the human mind evolves at a different rate. The
evolution gap drives much of the cognitive dissonance, distrust and dystopia around the ongoing
Fourth Revolution. In the upcoming data age, science is lost as a driver of democratic policy, when
there are no new frameworks for society as it confronts risk. With modest adjustment, the existing
model can guide us into the coming decades, with Europe still being a creative and respected thought
leader in the global risk community, provided that:
• by re-engaging with what we know about human society’s needs in terms of explanation and
empowerment, as well as risk management, institutions can better fulﬁl their ever-legitimate
roles;
• by focusing on the outcomes for which food safety systems stand, scientiﬁc evidence can also
guide and underpin the changes in method and tools that offer better results with lower
‘compliance friction’.
Successful data futures (for EFSA, and for Europe in general) should be based on Truth and
Science, Broad Goals, Trustworthy Processes, Fullest Participation, Innovative Mindsets and the right
tools (EPSC et al., 2016), along with the ﬁve Vs for data.
As such, the data age is characterised by (Olson, online):
• volume (public cloud will be needed, to store amounts of data that will exponentially grow);
• variety (requiring AI and neural learning, to understand and cross-reference data coming from
different and ever changing sources);
• velocity (5G internet, which continuously senses data from the real world); and by uncertainty
about data’s:
• veracity (requiring cybersecurity, distributed ledger technology (blockchain) and audit-bots);
• value (by asking the user, all the time).
3.1.2. The challenges of big data for European agencies
As an example, the EMA/HMA big data task force is working on ‘The challenges of big data for
European agencies’ (Heads of Medicines Agencies and European Medicines Agency, 2019). Big data,
e.g. data collected in real time from the real world, in large amounts are increasingly becoming
available for regulatory decision makers.
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Main tasks of the task force are: to map relevant sources of big data in its remit (completed
December 2017); to describe the current state, future state and challenges for regulatory expertise,
competencies, need to specify legislation and guidelines, data analysing tools and systems; and,
eventually, to generate a list of recommendations.
The path from real-world data to real-world evidence is, however, full of challenges, but has also
many opportunities to contribute to evidence-based decisions (e.g. for the beneﬁt of patients).
Agreement on data standards, quality, linkage to clinical outcomes, as well as interoperability, are key
challenges to address as we move forward.
3.1.3. Blockchain technology and regulatory science
The global food industry faces important governance challenges for which blockchain has been
proposed as a solution. The concept of distributed ledger technology has already been identiﬁed for its
value proposition from the perspective of different players in the food supply chain (producer,
distributor, retailer, consumer, regulator, enforcer, etc.). The importance of separating the truth from
the hype surrounding blockchain has been emphasised and identifying real-world examples that show
how it is being used to promote transparency, traceability, accountability, reduce fraud and improve
consumer trust. However, a note of caution is needed by examining some of the ways in which
blockchain as a new ‘trust machine’ could potentially be subverted by vested interests and considering
what the industry and regulators might be able to carry out to prevent this, as well as how innovations
such as AI and social machines might help.
When asking if blockchain can help regulatory science, several promising areas of research and
innovative practice were highlighted, as well as new opportunities:
• Food and feed supply chain: Blockchain can be used to uniquely identify and track the
provenance, stewardship and condition of Food and Feed at every step in the supply chain.
• Detect food substitution: Recent reports suggest that ‘up to a ﬁfth of meat tests in the UK
reveal unspeciﬁed DNA’ (Mackay, 2018) and that 41% of seafood samples tested in Canada
were mislabelled (Ruryk and Chung, 2018). Using blockchain to create a veriﬁable ledger of
food components and ingredients can help to prevent fraud by making it easier to identify
changes. Integrating biometrical data also holds promise: for example, Australia is currently
exploring how to record ‘chemical barcodes’ on blockchain to combat food counterfeiting.
• Preventing food-borne disease: Walmart is leading an effort, together with Nestle, Dole and
others, to seek a Farm-to-Grocery-Aisle View of the Food Supply Chain. Early results show that
it went from needing 6 days to 2 s to trace a contaminated product from shelf to source, after
implementing blockchain. It was explained how improving both the speed and precision of
source identiﬁcation also beneﬁts farmers, by avoiding unnecessary food destruction and
stigma, while also helping to build consumer trust and reduce costs.
• Real-time regulatory compliance: Companies such as Modum3 are coupling the internet of
things and cloud-based digital ledger approaches to monitor temperature-sensitive products
during freight transportation, automatically auditing compliance with regulations on storage
conditions, while helping to avoid transport-related spoilage.
• Scientiﬁc currency: Some of the future ways in which blockchain could be used to support
science and innovation include tracking unpublished negative research to aid open science for
better decision making, enabling academics to record their microcontributions to emerging
research or impact, and auditing incremental innovations that challenge regulatory
reclassiﬁcation.
3.1.4. Software beats animal tests at predicting toxicity of chemicals
On AI, it was recently found that ‘software beats animal testing at predicting toxicity of chemicals’
using data from an EU agency (Hartung, 2019). Nowadays much chemical safety information is
publicly available, raising the hope to facilitate the prediction of the toxicity of new chemicals. The
REACH Regulation (1907/2006) provided the possibility of using non-testing opportunities, including
Quantitative Structure–Activity Relationship (QSAR) and Read-across (RAx). RAx is the approach to
estimate the toxicity of a substance by comparison to known properties of similar substances. By
3 https://modum.io/
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analysing the data submitted after the ﬁrst REACH deadlines in 2010 and 2013, RAx resulted as the
predominant method to avoid new tests on animals.
This triggered new general initiatives with the common goal of improving the robustness of the
approach and the scientiﬁc endorsement for better regulatory acceptance. For example, the European
Chemicals Agency (ECHA) has published their Read-Across Assessment Framework (RAAF) to guide the
formal presentation of RAx data and the European project EU-ToxRisk4 works on eight case studies on
RAx with the engagement of industry and regulators.
The Center for Alternatives to Animal Testing (CAAT) in the USA and Europe has started a RAx
programme in 2014 to develop Good Read-Across Practice and through the analyses of the data in the
ECHA database of registered substances. At that time, the number of substances was about 10,000
and after transformation of the records into a computer-readable format, it was possible to improve
toxicity predictions exploiting the big data available. Analysing the six most common OECD toxicity
tests for reproducibility (consuming 55% of animals in safety testing in Europe), a reproducibility of
81% (balanced accuracy, sensitivity 70%) was found.
Today the system has expanded with data from PubMed and the US National Toxicology
Programme to 10 million structures, including 800,000 chemicals with millions of data points on
physicochemical and toxicological endpoints. The constructed models automate and extend the
regulatory assessment (RA) method of chemical classiﬁcation. The new approach, called read-across
structure–activity relationship (RASAR) uses machine learning to combine binary ﬁngerprints and
Jaccard distance to deﬁne chemical similarity and feature vectors for supervised learning. A boost in
predictivity was achieved by data fusion, i.e. each prediction was deduced from 74 different features.
The results are focused on nine endpoints: skin/eye irritation, skin sensitisation, acute oral/dermal/
inhalation toxicity, mutagenicity and acute/chronic aquatic toxicity. Predicting 190,000 toxicity
classiﬁcations of chemicals, this system provided high sensitivities and speciﬁcities that equal or even
surpass the predictivity of animal tests. For the six tests, for which animal study reproducibility could
be assessed, the RASAR resulted in 87% accuracy (sensitivity 89%).
Overall the work demonstrated that toxicological studies carried out using animal testing are only
81% reproducible, and only 69% reproducible for toxic chemicals. The RASAR predictions, fully based
on software and AI, obtained 87% (balanced) accuracy.
It is envisaged that similar results should be achieved in the realm of food safety: software should
strongly reduce animal testing in this area as well. The next challenge is how far regulatory bodies and
governmental agencies will promote and encourage such new possibilities offered by big data.
3.1.5. Managing data to manage evidence: social and technical challenges
On the route from managing data to managing evidence, both social and technical challenges
appear, such as the reuse of open research data. In this context, ‘reuse’ simply refers to the usage of a
data set released in open access by someone other than the originator. While calls for increasing data
sharing and interoperability have recently gained traction among science stakeholders, little information
is known about how scientists actually reuse data once these have been made available in open access.
Expectations for how much, how and by whom open data will be reused are often misplaced.
Research shows that, on average, among the many data sets a data repository can host, just a few
popular open data sets are highly reused, while most data sets are very rarely reused, or not at all (this is
also called ‘the long tail of data reuse’; Wallis et al., 2013) and is comparable with the citation of scientiﬁc
literature in general. Data curation (i.e. documenting and organising data into structured formats) is
necessary but not sufﬁcient for reuse: scientists reuse solely those data that are instrumental to their
own research agenda and workﬂows. Experimental data (as opposed to observational data) are the
hardest to reuse: the epistemic costs of learning about the data and the science behind it are often too
high, specialised knowledge cannot be easily formalised in metadata and ontologies.
Science open data can be reused for many goals. Scientists commonly reuse these for control,
comparison, or calibration, or (more rarely) to conduct meta-analyses and to train or test algorithms.
However, setting aside a few notable exceptions, scientists almost never reuse open data sets to
investigate novel research questions (i.e. for knowledge discovery). Scientists easily trust open data that
have been reused before, over and over again, by their colleagues. Newly released open data with no
record of reuse will need time to conquer scientists’ hearts, the adoption curve could take months, or
even years. Reputation, trust and pre-existing networks impact reuse as much curation practices.
4 http://www.eu-toxrisk.eu/
Managing evidence
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2019;17(S1):e170704
Communities of practice are the ultimate holy grail of data reuse. For all the reasons mentioned
above, it was pointed out that the most successful cases of data reuse originate from multilaboratory
collaborations that involve both the data creators and the new users.
3.2. Problem formulation
3.2.1. Ignorance and the community of knowledge
Asking people to explain how something works reveals an illusion of explanatory depth: typically,
people know less about how things work than they think they do. We over-estimate our knowledge of
common objects. We similarly overestimate our understanding of political policies. It was argued that this
illusion of understanding relates to living in a community of knowledge, guided by shared intentionality.
Our communities understand how things work and we fail to distinguish what we know from the
knowledge that resides in other people’s heads. What was drawn out was some of the implications of
these ideas for the importance of ferreting out expertise from parts of society in which it resides.
3.2.2. Human–computer sense-making models and the challenges of
incorporating AI
On problem formulation, human–computer sense-making models and the incorporation of AI are
real challenges. Multilevel computational cognitive models can provide opportunities for understanding
and engineering new systems for sense-making and decision making in complex domains, such as
intelligence analysis. A multilevel model of the human sense-making process is necessary to develop
optimally performing human–AI interaction systems. Such a model accounts for the different levels of
processes (psychological, rational and organisational) that occur at different time scales. Such
multilevel models have a number of beneﬁts. They allow researchers to predict:
• how difﬁcult it will be for someone to ﬁnd certain information;
• how much a person will learn from using a particular system;
• whether people will be biased in their information searches and sense-making;
• what kinds of credibility judgements people will make about information sources.
As such, models of human cognition in sense-making have informed the design and engineering of
higher performance systems. For the foreseeable future, AI components in complex sense-making tasks
will not be autonomous, rather they will work interdependently with human specialists and mixed
human–AI systems ‘teams’ pose new challenges and require new designs. Those designs can be
informed by new cognitive science research focused speciﬁcally on human–AI interaction in sense-
making tasks. A major challenge, going forward, is setting up successful human–AI interdependence.
The emerging standard model of cognitive processing and AI is about a fairly constrained, reasonably
well deﬁned set of tasks and domains, but, the world we live in is not well deﬁned, it is very open ended.
Current systems of AI are extremely difﬁcult to understand. They produce valuable predictions and
behaviour, but we often have difﬁculty explaining how or why these were produced. This inﬂuences
trust, as people tend to trust those things that they understand or are familiar with. Explainable AI is one
of the major new ﬁelds of research relevant to sense-making and decision-making systems.
3.2.3. Open source software paradigm: using ethics to promote technology and
minimise its risks
Free and open source software (FOSS) has been at the heart of the ongoing information age for
more than three decades, to an extent that today it is impossible to underrate its value, ignore its
inﬂuence or challenge its momentum. As such, there exists an ‘open source software paradigm’ and
ethics can be used to promote technology and minimise its risks. FOSS has been perceived, during
such period. Not only as the driving force of innovation, but also as an inspirational moral architecture,
warranting the equitable sharing of beneﬁts from the digital transformation of society.
An evidence-based approach was presented to showcase the overall potential and the perspectives
offered by FOSS today. The central tenet of the presentation revolved around FOSS maturity, and
several aspects were demonstrated, such as FOSS’s readiness:
• to support effectively today’s complex information architectures;
• to operate reliably critical business applications;
• to help reduce the risks of proprietary solutions by avoiding costly vendor lock-in.
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The capabilities offered by FOSS today allow the co-shaping of new technologies such as AI, cloud
computing and big data. Emerging FOSS products, new licensing modes and business models were
presented, along with FOSS costs, beneﬁts and risks. These were all with a view to understand the
current FOSS potential at a time of transition and its present relevance in a context of ﬁnancial, social
and environmental crisis that public organisations are facing.
In this context, the FOSS initiatives in global organisations with emphasis on the EU bodies were
overviewed. Their experience has been crystallised in a host of best practices and strategic policy
initiatives, e.g. the digital single market, the new General Data Protection Regulation (GDPR), the
digital workplace, the future of work etc. FOSS capabilities to support reliably public organisations at
optimal cost, ﬂexibility and signiﬁcant innovation potential were highlighted. Strategic considerations
and key drivers in selecting, building and operating FOSS solutions have been set in perspective with
technology governance and policy implications for society and for the economy at large.
3.3. Evidence integration
3.3.1. Integrating mechanistic evidence from evolving sources in hazard and risk
assessment
Within integrating mechanistic evidence from evolving sources in hazard and risk assessment,
modern concepts such as MOA and AOP are conceptually similar constructs that organise mechanistic
knowledge as a sequence of measurable key events at different levels of biological organisation
(Lanzoni et al., 2019). AOPs address chemically agnostic key events between the initial interaction of a
chemical with a molecular target (the molecular initiating event (MIE)) and adverse or disease
outcomes. MOA analysis for hazard characterisation includes additional consideration of the chemical-
speciﬁc aspects of disposition to the target (toxicokinetics and metabolism).
These pathway descriptions facilitate integrating and assessing mechanistic data in hazard and risk
assessment from a broad range of sources including structure–activity analysis, in vitro assays, toxicity
tests in animals and observational or clinical studies in humans. Linkage of MIEs and early key events
measured in higher throughput systems to adverse effects characterised in traditional testing strategies
is also anticipated to advance more tailored, efﬁcient and predictive testing strategies.
The development and description of AOPs has been formalised in a public knowledge base to
support their use for various applications in testing and assessment within an OECD programme. The
associated Guidance and Users Handbook outlines conventions, terminology and relevant information
content, including a structured assessment of the extent of supporting evidence. WoE is characterised
based on a subset of the Bradford Hill (B/H) considerations applied to assess causality in
epidemiological studies and tailored, more recently, for application to mechanistic data in international
frameworks for MOA analysis. Examples of the nature of data sets associated with high, moderate and
low conﬁdence for the deﬁned considerations were provided. The considerations have also been rank
ordered to reﬂect their relative importance and the extension of the approach to enable quantitation of
comparative WoE is being considered.
This structured and systematic consideration of the extent of mechanistic evidence in a coordinated
construct, such as the AOP, facilitates its use for various regulatory applications for which different
degrees of conﬁdence are required. Coordinated consideration early in AOP development also focuses
research efforts to meet speciﬁc regulatory need, based on critical data gaps.
3.3.2. Foodomics 2.0
‘Omics have found their way into food and nutrition too. ‘Foodomics 2.0’ was deﬁned a decade ago
as ‘a discipline that studies the food and nutrition domains through the application and integration of
advanced ‘omics technologies to improve consumer’s well-being, health and knowledge’. Foodomics 2.0
is warranted as all of the underlying technologies have had signiﬁcant upgrades over the past years.
Molecular characterisation is currently available at an unprecedented scale. In addition, downstream
(big) data analysis had evolved and adopted insights/methods from ﬁelds ranging from information
and communications technology (ICT) (computer science and database technology) through statistics/
machine learning and AI. In many ways our biggest bottleneck is our ability to draft realistic,
interesting, but non-trivial questions around nutrition and health. A plethora of current and (near)
future applications of molecular proﬁling in food sciences has been presented as Foodomics 2.0 is
getting ready for personalised nutrition.
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Nutri(epi)genomics is ‘a discipline that studies the food and nutrition domains through the
application and integration of advanced ‘omics technologies to improve consumer’s well-being, health
and knowledge’. Some examples were described on declination of foodomics in different domains,
including: (i) genetics (nutrigenomics); (ii) epigenetics (nutri-epigenetics); (iii) metagenomics (nutri-
metagenomics); and (iv) examples in applied technology on big data/AI.
As concerns genetics and nutrigenomics, 5 years ago it was already possible to have access to
services for creation of a personal protein proﬁle in a digital ﬁle, and even to have a 3D printing of
one’s own proteins. In 2017, the consumer genomics market expanded rapidly with genetic testing
able to offer to consumers a number of tests spanning ancestry to love ﬁnding. When questioning
what we actually can do with consumer genetics, Wobblebase’s5 work bridges the gap between
consumers and medical professionals to leverage genetic information to its fullest potential. For
instance, an app has been developed that is able to identify pills with a phone camera, unravel their
ingredients and provide the user with a report on their own single nucleotide polymorphisms (SNPs)
and sensitivity to medicines, based on interrogation of pharmacogenomics databases. In nutrition, a
similar approach can be used to scan barcodes on food, identify the ingredients and check consumer’s
SNPs against sensitivity to ingredients such as peanuts or to allergens.
Epigenetics makes it possible to reuse one genome for many different purposes and is driving the
aetiology of many human diseases, and we can inﬂuence changes in the epigenetics. The relative
importance of epigenetics is that food is inducing changes in DNA (expression) continuously! There is
an integration of intrinsic and environmental signals: food can switch-on or switch-off genetics and so
modulate its functioning as it happens, e.g. queen bee development following nutrition with royal jelly.
While the genetic code in DNA is not the target, changes in histones and methylation of DNA bases,
for example, can modulate gene expression.
Metagenomics describe that a healthy adult hosts have ca. 100 trillion bacteria in the gut alone and
the communal gut microbial genome (microbiome) is ca. 150 times larger than the human genome. It
is reasonable to view the microbiome as some sort of an organ by itself, for which there are kits
available on the market (uBiome6) that are able to measure metagenomics proﬁles using machine
learning, AI, advanced statistical techniques and sequencing technologies.
There are already home version portable and very cheap laboratory equipment available on the
market (Foodomics 3.0), such as a ‘Minima’ kit for consumers who want to test the origin of their food
in 1 or 2 h at home. This kit is based on a DNA ampliﬁcation technique via loop-mediated isothermal
ampliﬁcation (LAMP7 ). Such miniaturised portable, real-time sequencing devices are as small as a
mobile phone and can be readily plugged into a laptop. Indeed, testing is getting closer to the user,
and can be carried out at home.
Similarly, a large amount of information (big data) is available on the combination of foods. AI and
text mining can be used to screen this information to survey food recommenders (Anderson, 2018) or
to understand and exploit the science behind food pairing to discover new food pairs.8
3.3.3. Network-based integration of molecular ‘omics data
Networks can facilitate the integration of molecular ‘omics data. Interaction networks in which
nodes represent biological entities, such as genes, gene products, metabolites, etc., and edges
represent the interactions between the nodes, provide a comprehensive way of summarising all
available molecular information known about an organism of interest. These networks can be used not
only to visualise biological data, but can also serve as a scaffold to analyse one’s own in-house
generated data sets. Network models, built on prior interaction networks, provide an intuitive way to
integrate heterogeneous ‘omics data and demonstrate why network models are so powerful. An
example was provided on how cohort analysis can be used to assess the efﬁciency of drug responses
or to unveil the molecular mechanisms that result in antibiotic resistance development.
‘Omics data can be used for food safety, for instance for assessing the molecular signature of a
toxic compound. Transcriptomics can for instance show which genes are upregulated or downregulated
in relation to exposure to a certain food. Expression proﬁles of individuals can be used as a molecular
phenotype to identify molecular signatures that can be used as biomarkers and ideally unveil the MOA
of toxicity. In personalised nutrigenomics, via genomic biomarkers, one could determine whether or
5 https://doc.ai/
6 https://ubiome.com/
7 http://minimabiolab.org/project/
8 https://www.foodpairing.com/en/home
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not an individual will elicit a toxic response in respond to a certain toxicant. Identifying genomic
biomarkers requires ‘omics-based cohort analysis.
The use of network-based analysis increases the possibility of detecting changes, as well as
increasing the power of analysis. These networks exploit prior information on molecular interactions as
a scaffold to drive the analysis, steering the solution of the data-integration problem to the most
biologically relevant network. Networks basically provide an intuitive scaffold to integrate data.
Network-based analysis of ‘omics data can allow the search for pathways that contain signiﬁcantly
more variants in the responder set than in the non-responder set. Both single network models and
complex network models can be used, using different data sources. Network-based analysis of ‘omics
data also can provide insight into mechanism of disease.
3.3.4. EFSA’s Scientiﬁc Colloquium on ‘omics in risk assessment
In research, ‘omics data has been used for more than a decade to study basic biological problems
and vast amounts of analytical data are being collected and shared in public database; however ‘omics
data and its approach are not (yet) used very much in risk assessment. ‘Omics data sets are starting
to be used in some risk assessment areas and are used as complementary to or as a substitute for
classical data.
It is clear that ‘omics have now entered the domain of food safety, nutrition and risk assessment.
Already in 2014, EFSA started mapping the use of ‘omics tools in risk assessment related to food and
feed safety and to review modern methodologies and tools for human hazard assessment of
chemicals. This process has continued with EFSA’s 24th Scientiﬁc Colloquium on ‘Omics in risk
assessment: state of the art and next steps’ that took place in Berlin, Germany on 24–25 April 2018
(for programme and presentations, see http://www.efsa.europa.eu/en/events/event/180424-0). The
Scientiﬁc Colloquium aimed to take into account the latest advancements and explore the potential use
of ‘omics data sets to support scientiﬁc safety evaluation. It addressed the question ‘are there concrete
possibilities of implementation of ‘omics in risk assessment?’.
The outcome of the Colloquium intends to support risk assessors in the process of incorporating
‘omics tools into the risk assessment of food and feed products. An event report summarising the
outcomes of the Colloquium was published in 2018 (EFSA, 2018).
Outcomes of this event indicate that ‘omics studies are used to characterise and quantify the roles
and relationships of large sets of different types of molecules in an organism to collate information on
the functional status or impact of environmental factors on an organism. In recent years, the
development of innovative tools in genomics, transcriptomics, proteomics and metabolomics
(designated collectively as ‘omics technologies) has opened up new possibilities for applications in
scientiﬁc research and led to the availability of vast amounts of analytical data. Omics are used to
characterise and quantify the roles and relationships of large sets of different types of molecules in an
organism. Genomics can facilitate the analysis of entire or component genome sequences of an
organism. Transcriptomics and proteomics provide signiﬁcant bodies of information on temporal and
spatial expression of genes and gene products, respectively, while metabolomics captures data for a
large pool of metabolites. The interpretation and integration of ‘omics data can provide valuable
information on the functional status of an organism and on the impact of external factors, e.g.
stressors.
The Colloquium explored the opportunities for integration of data sets produced via speciﬁc ‘omics
tools within the remit of EFSA’s risk assessment approaches and has built further towards a concrete
path of implementation. Discussions in the Colloquium focused on a set of topics for which EFSA
intends to exploit ‘omics data sets to support scientiﬁc safety evaluation. These topics are: genomics in
microbial strain characterisation; metabolomics for the comparative assessment of genetically modiﬁed
(GM) plants; and the use of ‘omics for toxicological and environmental risk assessment.
In summary, outcomes and discussion of the 24th Colloquium highlighted that:
• ‘omics data are an important tool, e.g. in elucidating mechanisms and determining MOAs and
AOPs;
• ‘omics data can be integrated into risk assessment in several areas, albeit that there are
development needs (reference data sets, information on baseline variability, quality and
reporting standards, development of expertise);
• ‘Omics data are already part of risk assessment data in EFSA (WGS data in analysis of food-
borne diseases and for GM plants);
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• challenges are linked to:
– storage/cloud-based storage;
– data analysis (development of software tools and expertise);
– setting quality standards and developing guidelines;
– interpretation in risk assessments and developing guidelines.
3.3.5. From ‘WoE’ to quantitative data integration
Finally, within evidence integration, the audience was informed on the topic ‘From ‘WoE’ to
quantitative data integration’. In line with the recent EFSA activity on WoE (EFSA Scientiﬁc Committee,
2017), WoE is an approach that, by means of qualitative or quantitative methods, integrates individual
lines of evidence to form a conclusion. Contemporary WoE methodologies have advanced with the
evolution of statistical science (see Linkov et al., 2015 for review). In the 1960s, it was proposed that
WoE processes should follow an inherently Bayesian statistical approach in which ‘prior’ beliefs for or
against a particular hypothesis are updated after evaluation of information or evidence to achieve a
‘posterior’ belief. It has evolved in multiple methods and tools with varying degree of quantitative rigour
and reliance on judgement. From commonly used listing evidence and best professional judgement all
the way through quantitative MCDA and Bayesian methods, all the methods are captured to a varying
degree by recent WoE recommendations and approaches that have been expanding recently. Multiple
applications of these methods for food safety and related areas have been reported and have been
summarised in this presentation. It was argued that successful application of WoE to food safety
requires standardisation to produce consistency and comparability across ongoing WoE efforts.
It is essential that the WoE methodology used in risk assessment moves from qualitative
approaches that are commonly not used to quantitative analysis and decision making. Increased rigour
of analysis can help to:
• determine if there is enough evidence to support a determination or action (e.g. justiﬁcation
for a speciﬁc threshold);
• compare alternative courses of action or selected alternative agents of processes to see what
is better supported (e.g. selection of the most likely MOA);
• identify gaps in understanding and prioritise research;
• highlight scientiﬁc consensus to bolster use of an approach/tool.
Any selected WoE methodology needs to reﬂect the reason for the analysis, and MCDA methods
(Cegan et al., 2017) can help here. The following aspects on MCDA methods are to be noted:
• MCDA methods have evolved as a response to the observed inability of people to effectively
analyse multiple streams of dissimilar information;
• Many different MCDA approaches are based on different theoretical foundations (or
combinations);
• MCDA methods provide a means of integrating various inputs with stakeholder/technical expert
values and means of communicating model/monitoring outputs for regulation, planning and
stakeholder understanding;
• MCDA approaches can guide collection of additional information through the value of
information analyses;
• Risk-based MCDA offers an approach for organising and integrating varied types of information
to perform rankings and to better inform decisions.
Several recent applications of quantitative WoE clearly show its value for regulatory decision making
in the context of EFSA interests (Linkov et al., 2011; Becker et al., 2015; Collier et al., 2016).
4. Conclusions
In the ﬁnal forum discussion, the ﬁndings and presentations of the day were summarised and
analysed in depth.
Exploration of all plausible data streams, including from the general public, could generate useful
information to inform future scientiﬁc work. To be able to source knowledge and information available
in the public domain, existing IT platforms need to be explored or developed to facilitate the
harvesting and exchange of data and ideas using crowdsourcing. An assessment of data quality
(ﬁtness for purpose) before use is a prerequisite in this regard.
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While keeping in mind that the world is going through an exponential explosion of data, potentially
increasing the evidence base for risk assessments, it becomes relevant to consider how we can explore
and analyse all these data.
Besides the requirements of new tools and approaches such as machine learning and AI, the
session addressed the challenges ahead with respect to targeting, analysing and accessing the right
data serving as evidence, and reﬂecting on the ways in which this diverse body of evidence could be
used to provide ﬁt-for-purpose risk assessments.
We are now facing many sources of evidence, many sources of knowledge and many different
ways of incorporating them. The trade-off between qualitative and quantitative risk assessment was
discussed, and how big data can inﬂuence both. A residual level of uncertainty will always exist, both
due in biases in deﬁning a model, and possible non-uniform coverage in the collection of big data. It is
as well forecasted that risk assessment will not be totally automated, and there will still be a residual
role for expert judgement. An agreed point is that we need, in the future, a better way to record
decision making, to improve quality and transparency.
It has been discussed how to avoid the apparent dichotomy between randomised trials and
observations from the ‘real world’, and how the two can be integrated to decide on causality and
improve evidence-based decisions.
The advantages and disadvantages of ‘real-world’ observations have been analysed, being
conscious that different perspectives of the same reality can be observed, leading to different purposes
of collection of big data, and therefore making data reusage difﬁcult.
B/H criteria were discussed and considered as a possible decision model, while biological plausibility
was discussed from several point of views, including being a criterion of coherence between theory
and the ‘real world’.
The panel did agree on the difﬁculty of integrating ‘omics and AOP.
As a summary, the three main aspects of the session have been:
• (big) data availability and (big) data connection;
• importance of problem formulation;
• evidence integration.
The ﬁrst topic considered the current situation of the increasing availability of a wide range of
evidence.
Future areas of research should include: (i) volume: the need for an EFSA public cloud; (ii) variety:
the need for AI and neural learning; (iii) velocity: the need for a 5G internet of food, that continuously
senses data from the real world; (iv) veracity: the need for cybersecurity, distributed ledger technology
(blockchain) and audit-bots; and (v) the need to determine and document value: we need to ask users.
More relevant technologies in the area of scientiﬁc risk assessment were explored: molecular
biology; ‘omics, big data, the internet of things.
Blockchain technology was explored as promising technology for data traceability and traceability in
the whole food chain.
In human health risk assessment, the potential for software to increase the capacity to predict
toxicity of some chemicals has been demonstrated.
The second topic underlines the increasing importance of problem formulation in a human and
societal dimension.
The importance of crowdsourcing to aggregate diverse expertise has been demonstrated, along
with the possible usage of blockchain as a sophisticated method for effectively sharing reputation and
creating trust.
Sense-making has been discussed as aid in designing computer systems that effectively and
sensibly augment the performance of humans.
The third topic deals with WoE assessment, including evidence integration and uncertainty analysis
and explores the applications of machine learning and AI in scientiﬁc risk assessment.
‘Omics combined with big data sets, large computational power and machine learning can be
integrated into the risk assessment to cover several of areas, although there are development needs
(e.g. reference data sets, information on baseline variability, quality and reporting standards, develop
expertise). Moreover, several challenges need to be overcome in terms of storage (? cloud-based
storage), data analysis (? software tools and expertise development), setting quality standards (?
guideline development) and interpretation for risk assessment (? guideline development).
MOA and AOP are complementary disciplines to assimilate mechanistic data to move us from the
observation in animal studies to more predictive approaches, by assimilating biochemical and biological
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mechanistic information on disease pathways at a broad range of biological levels of organisation. This
can be extremely useful for a range of regulatory applications (e.g. development of testing strategies,
considerations on biological plausibility in epidemiological studies, MOA analysis for speciﬁc chemicals
or groups, environmental monitoring).
WoE methodology is essential to move from qualitative to quantitative analysis and decision
making. It helps to: determine if there is enough evidence to support a determination or action
(threshold); compare alternatives to see what is better supported (carcinogen MOA); identify gaps in
understanding; and highlight scientiﬁc consensus to bolster use of an approach/tool.
MCDA methods have evolved as a response to the observed inability of people to effectively analyse
multiple streams of dissimilar information. Many different MCDA approaches exist based on different
theoretical foundations (or combinations). They provide a means of integrating various inputs with
stakeholder/technical expert values, and of communicating model/monitoring outputs for regulation,
planning and stakeholder understanding. Risk-based MCDA offers an approach for organising and
integrating varied types of information to perform rankings and to better inform decisions.
5. Recommendations
The session has led to several recommendations from which EFSA can proﬁt and which it can enrol
in its future strategy (on data and evidence):
• To base EFSA’s data futures on truth and science, broad goals, trustworthy processes, fullest
participation, innovative mindsets and the right tools;
• The data age is characterised by the volume, variety and velocity of data generation, as well
as their veracity and value;
• To further explore the strengths and limitations of the combined use of ‘big data’ and AI for
risk assessment purposes, and consider development needs for its practical implementation;
• To further explore the strengths and limitations of biotechnological tools such as ‘omics for risk
assessment purposes, and consider development needs for their practical implementation;
• To further develop global partnerships to share and leverage data and analytical methodologies
capturing, analysing and using these new types of data and data sources in risk assessment;
• To further explore the strengths and limitations of MOA and AOP approaches for risk
assessment purposes, and consider development needs for their practical implementation;
• To further explore the strengths and limitations of the WoE methodology for risk assessment
purposes, and consider development needs for its practical implementation;
• To further explore the strengths and limitations of MCDA methods for risk assessment
purposes, and consider development needs for their practical implementation;
• To further explore the strengths and limitations of Blockchain technology for risk assessment
purposes, and consider development needs for its practical implementation. Several promising
areas of research have been identiﬁed:
– scientiﬁc currency – blockchain technology as ‘trust machine’;
– food/feed supply chain: blockchain technology can be used to uniquely identify every
element of the food/feed supply chain;
– food substitution: blockchain technology can be used to detect ‘fakes’ in the food chain;
– preventing food-borne diseases: industries and wholesales are leading an effort to seek a
farm-to-grocery-aisle view of the food supply chain.
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Abbreviations
AI artiﬁcial intelligence
AOP adverse outcome pathways
API Application Processing Interface
B/H Bradford Hill
CAAT Center for Alternatives to Animal Testing
ECHA European Chemicals Agency
EMA European Medicines Agency
FOSS Free and open source software
GDPR General Data Protection Regulation
GM genetically modiﬁed
HMA Heads of Medicines Agencies
ICT information and communications technology
LAMP loop-mediated isothermal ampliﬁcation
MCDA multicriteria decision analysis
MIE molecular initiating event
MOA mode of action
QSAR Quantitative Structure–Activity Relationship
RAAF Read-Across Assessment Framework
RA regulatory assessment
RASAR read-across structure–activity relationship
RAx Read-across
SNP single nucleotide polymorphism
WoE weight of evidence
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